Grenas Cheryl Yvonne 4

What Happened
Cheryl Yvonne Grenas, a director of Nutex Health, was granted 603 restricted stock units (RSUs) on July 14, 2025. The RSUs were reported as acquired at $0.00 (a derivative award), meaning no cash was paid at grant; each RSU represents a contingent right to receive one share upon vesting.

Key Details

• Transaction date and type: July 14, 2025 — Award/Grant of 603 RSUs (derivative, code A), $0.00 per unit.
• Vesting: 100% vesting on July 14, 2026. If the reporting person leaves service without cause during the vesting period, the RSUs vest on a pro‑rata basis for time in service (footnotes F1, F2).
• Shares owned after transaction: not stated in the provided filing.
• Filing timeliness: Form 4 was filed Feb 9, 2026 — about seven months after the grant date, which appears late relative to the usual two-business-day SEC reporting requirement; late filings reduce transparency for investors.

Context
RSUs are conditional compensation that convert to actual shares only upon vesting; they are not an open‑market purchase or sale and do not reflect an immediate cash investment by the insider. Director RSU grants are a common form of compensation; retail investors should view this as a compensation award rather than a direct buy/sell signal.